AlgiPharma AS is dedicated to the development and commercialization of novel therapeutics, based on our patented alginate oligomer technology, that will help transform the lives of patients with severe or chronic diseases: Helping patients and their families towards a better day. AlgiPharma is a clinical stage biopharmaceutical company with a primary focus on respiratory diseases and other conditions caused by microbial infections and biofilms. Our aim is to address unmet medical needs and fight diseases effectively through our innovative alginate technologies. Our alginate technology targets those diseases where there is a clinical need to mitigate abnormal mucus accumulation, microbial infection, biofilm formation and antibiotic resistance. AlgiPharma is developing its first drug candidate for patients with Cystic Fibrosis (CF), where we hold orphan drug status with EMA and FDA. To date we have won almost USD 40 million in Government and NGO support including USD 14,5 million from the American Cystic Fibrosis Foundation. We have completed 5 clinical trials to date and have one ongoing clinical trial as well as one phase 2b multinational trial approved and just about to start recruitment. The AlgiPharma technology has multiple applications including other respiratory diseases such as COPD, bronchiectasis etc. Other applications include treatment of microbial infections, bacterial and fungal biofilm prevention and disruption, including wound healing, surgical procedures and on medical devices.
Chief Medical Officer / Director Clinical Research
We are looking for a dedicated and structured candidate to lead our clinical team at AlgiPharma. Depending on the candidate profile, this could be either a Director of Clinical Research or Chief Medical Officer.
The candidate will be responsible for the overall clinical development and participate in the regulatory strategy from pre-clinical to marketing in different therapeutic indications – primarily respiratory diseases for now. The company is about to start a pivotal phase IIb/III trial with its lead drug candidate OligoG in the orphan indication cystic fibrosis.
As Director Clinical Research / Chief Medical Officer you are responsible to plan and execute the clinical development, participate in interactions with regulatory authorities, contribute to market research and launch preparations, participate in development of pharmaco-economic assessments for use in pricing and reimbursement negotiations, stay up-to-date on science in the field where AlgiPharma operates, participate in relevant scientific or disease specific meetings to promote AlgiPharma`s technology, science and clinical results, in addition to understanding recent developments in relevant disease areas.
We are looking for high calibre candidates who are motivated to be central in the team bringing AlgiPharma’s first products to market.
The ideal candidate has:
- Medical Doctor or Master’s degree or higher in medicine, pharmacy, biochemistry, biology or similar field
- At least 10 years relevant experience from the pharmaceutical/biotech/medical device industry
- First-hand experience with bringing a drug to market, regulatory and reimbursement success
- First-hand experience with running clinical studies in the US and Europe
- Knowledge of EU and FDA regulations and their practical implementation
- Excellent communication skills
The ideal candidate will be a highly motivated individual with experience from and interest in working in a small, entrepreneurial environment with broad responsibilities and opportunities.
We offer an engaging working environment at a dynamic company close to delivering the first of its drug candidates to market. We offer a competitive remuneration package
—
For more information, please contact external recruiter, Borka Consulting AS:
André Borka at +47 908 31 871 or andre@borka.no.
Please send your application (both motivational letter and CV) in PDF format to andre@borka.no.
Interviews are held consecutively, please show your interest as soon as possible!
All inquiries are treated confidentially, also towards AlgiPharma in the initial phase if desired.
.
